Esperion Therapeutics (acquired) is Drug Discovery in United States that focus on cardiometabolic risk markers business. Founded in 1998. They cover business area such as developer, pharmaceutical product, cardiovascular and metabolic disease, research, development, commercialization, oral, low-density lipoprotein cholesterol, therapy, patient, hypercholesterolemia.
1998
( 28 years old in 2026 )
Cardiometabolic Risk Markers
-
46701 Commerce Center Drive
Suite B
Plymouth, MI 48170
United States
Private
developerpharmaceutical productcardiovascular and metabolic diseaseresearchdevelopmentcommercializationoral, low-density lipoprotein cholesteroltherapypatienthypercholesterolemia
* We use standard office opening hours in near Esperion Therapeutics (acquired)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Esperion Therapeutics (acquired) is Drug Discovery business from United States that founded in 1998 (28 years old in 2026), Esperion Therapeutics (acquired) business is focusing on Cardiometabolic Risk Markers.
Esperion Therapeutics (acquired) headquarter office and corporate office address is located in 46701 Commerce Center Drive Suite B Plymouth, MI 48170 United States.
Esperion Therapeutics (acquired) was founded in United States.
In 2026, Esperion Therapeutics (acquired) is currently focus on cardiometabolic risk markers sector.
Above is snippet of Google Trends for "cardiometabolic risk markers" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Esperion Therapeutics (acquired), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
